Want to see SE:QLINEA full AI Analyst Report?
QLINEA Stock Chart & Stats
kr18.50
-kr0.25(-1.52%)
At close: 4:00 PM EDT
kr18.50
-kr0.25(-1.52%)
Day’s Range― - ―
52-Week Rangekr14.55 - kr38.43
Previous CloseN/A
Volume661.00
Average Volume (3M)4.93K
Market Cap
kr315.50M
Enterprise Valuekr147.98M
Total Cash (Recent Filing)kr186.77M
Total Debt (Recent Filing)kr11.68M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.20
Shares Outstanding18,949,081
10 Day Avg. Volume3,230
30 Day Avg. Volume4,928
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits the immediate burden of borrowings and preserves more financial flexibility than a highly indebted structure would. Positive equity also provides a current buffer, although continued losses could weaken that protection if they persist.
Recurring Consumables ModelThe platform is designed to generate repeat consumables revenue as instruments are used for additional patient samples. This creates a more scalable and potentially durable revenue stream than relying only on occasional analyzer sales or placements.
Rapid Infectious Disease FocusThe company targets clinical decisions where faster identification of effective antibiotics may improve treatment choices, particularly in severe infections such as sepsis. That focused diagnostic purpose supports a durable role within hospital microbiology workflows.
Bears Say
Heavy Cash BurnMaterially negative operating and free cash flow show that operations continue to consume substantial cash rather than funding themselves. Persistent burn can reduce financial flexibility, increase dependence on external funding, and constrain investment in commercialization and product development.
Severe UnprofitabilityLosses across gross, operating, and net levels indicate that the current cost structure has not yet become economically viable. Until margins improve sustainably, revenue growth may not translate into stronger earnings or internally generated funds for expansion.
Prior Equity StressThe history of negative equity demonstrates that continued losses have previously eroded the balance-sheet cushion available to shareholders. Strongly negative returns on equity reinforce the concern that capital is not currently producing sustainable shareholder value.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr14.55 and its highest was kr38.42 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr315.50M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Oct 30, 2026 which is in 11 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Jul 10, 2026. The company reported -kr1.58 earnings per share for the quarter.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -kr1.58 in its last earnings report. Following the earnings report the stock price went up 7.453%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.